Chih-Yi Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chih-Yi Liao has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Caixia Sun
TransThera Sciences (Nanjing), Inc., Nanjing, China
25 shared publications - Farshid Dayyani
University of California Irvine 3 Division of Hematology/Oncology, Department of Medicine Orange, California
25 shared publications - Frank Wu
TransThera Sciences (Nanjing), Inc., Nanjing, China
25 shared publications - Hui Wang
TransThera Sciences (Nanjing), Inc., Nanjing, China
25 shared publications - Jean Fan
TransThera Sciences (US), Inc., Gaithersburg, Maryland
25 shared publications - Katie Hennessy
TransThera Sciences (US), Inc., Gaithersburg, Maryland
25 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1214
A Pilot Study of Dynamic Circulating Tumor Cell Profiling for Patients with Hepatocellular Carcinoma Receiving Systemic Therapy
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer morbidity and mortality, and patients are often diagnosed with advanced disease or metastasis at time of diagnosis. Characterizing circulating tumor cell (CTC) behavior may shed light on the disease’s natural history and treatment response. Methods: We used a commercially available, size-based microfluidic purification technology to isolate CTCs from the whole blood of an exploratory prospective cohort of 23 patients receiving systemic therapy for HCC, both prior to treatment and after 6–8 weeks of treatment. CTC concentrations were quantified using on-chip staining with a cocktail of HCC-specific antibodies followed by rare cell image analysis. CTC counts were correlated with standard laboratory and clinical parameters. Results: Our assay’s sensitivity was higher than previously published. CTC counts did not correlate with disease stage or on-treatment survival. Pre-treatment CTC counts were inversely related to serum alpha-fetoprotein (AFP) levels and were not correlated with circulating tumor DNA quantitative metrics or genomic subsets. On-treatment increase in CTC counts showed a non-significant trend toward improved survival. Conclusions: Serial CTC enumeration on therapy may serve as a novel liquid biopsy approach that complements the data yielded by conventional biomarkers like AFP and ctDNA. Future work will better define how deeper characterization of CTC dynamics and expression profiling can contribute to biomarker development.
- 13 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1214
Open AccessA Pilot Study of Dynamic Circulating Tumor Cell Profiling for Patients with Hepatocellular Carcinoma Receiving Systemic Therapy
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer morbidity and mortality, and patients are often diagnosed with advanced disease or metastasis at time of diagnosis. Characterizing circulating tumor cell (CTC) behavior may shed light on the disease’s natural history and treatment response. Methods: We used a commercially available, size-based microfluidic purification technology to isolate CTCs from the whole blood of an exploratory prospective cohort of 23 patients receiving systemic therapy for HCC, both prior to treatment and after 6–8 weeks of treatment. CTC concentrations were quantified using on-chip staining with a cocktail of HCC-specific antibodies followed by rare cell image analysis. CTC counts were correlated with standard laboratory and clinical parameters. Results: Our assay’s sensitivity was higher than previously published. CTC counts did not correlate with disease stage or on-treatment survival. Pre-treatment CTC counts were inversely related to serum alpha-fetoprotein (AFP) levels and were not correlated with circulating tumor DNA quantitative metrics or genomic subsets. On-treatment increase in CTC counts showed a non-significant trend toward improved survival. Conclusions: Serial CTC enumeration on therapy may serve as a novel liquid biopsy approach that complements the data yielded by conventional biomarkers like AFP and ctDNA. Future work will better define how deeper characterization of CTC dynamics and expression profiling can contribute to biomarker development.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Pharmacokinetic Parameters of Doses at Cycle 1 Day 28 in Arm C.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Pharmacokinetic Parameters of Doses at Cycle 1 Day 28 in Arm C.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Frequency of selected genomic alterations and PFS in TNBC and aTNBC.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Frequency of selected genomic alterations and PFS in TNBC and aTNBC.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Overview of baseline mutations among patients with breast cancer (A), selected mutations in responders versus nonresponders (B), and relative change in VAF from baseline to cycle 3 days 1 (C).
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Overview of baseline mutations among patients with breast cancer (A), selected mutations in responders versus nonresponders (B), and relative change in VAF from baseline to cycle 3 days 1 (C).
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Inclusion and Exclusion Criteria.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Inclusion and Exclusion Criteria.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Time to PFS According to RECIST 1.1.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Time to PFS According to RECIST 1.1.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Hypertension Management Guidelines.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Hypertension Management Guidelines.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Gene List for the FoundationOne Liquid CDx Assay.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Gene List for the FoundationOne Liquid CDx Assay.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Fleming’s Two-Stage Design for Enrollment of Each Preferred Indication.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Fleming’s Two-Stage Design for Enrollment of Each Preferred Indication.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Prior Lines of Therapies for Cholangiocarcinoma, Breast Cancer, and Prostate Cancer Populations as well as Total Population (A) and Baseline FGFR Status (B).
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Prior Lines of Therapies for Cholangiocarcinoma, Breast Cancer, and Prostate Cancer Populations as well as Total Population (A) and Baseline FGFR Status (B).